Compare SBET & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | PCRX |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2025 | 2010 |
| Metric | SBET | PCRX |
|---|---|---|
| Price | $5.18 | $36.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 9 |
| Target Price | $16.13 | ★ $33.57 |
| AVG Volume (30 Days) | ★ 9.4M | 944.4K |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.89 |
| Revenue | $28,055,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $81.28 | $3.84 |
| Revenue Next Year | $47.36 | $4.73 |
| P/E Ratio | ★ N/A | $40.99 |
| Revenue Growth | ★ 666.04 | 26.04 |
| 52 Week Low | $4.46 | $18.80 |
| 52 Week High | $12.29 | $36.67 |
| Indicator | SBET | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.32 | 82.36 |
| Support Level | $5.06 | $22.00 |
| Resistance Level | $5.90 | $36.67 |
| Average True Range (ATR) | 0.38 | 0.04 |
| MACD | -0.10 | -0.38 |
| Stochastic Oscillator | 4.79 | 86.67 |
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.